{"gene":"CHN2","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1994,"finding":"β2-chimaerin (CHN2) was identified as a 46-kDa RacGAP protein specifically expressed in cerebellar granule cells, possessing an N-terminal SH2 domain generated by alternative splicing of the beta-chimaerin gene. It is enriched in particulate/synaptosomal fractions and its expression increases postnatally.","method":"cDNA cloning, PCR, immunoblotting, subcellular fractionation, immunohistochemistry in rat cerebellum and mouse weaver mutant","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (cloning, fractionation, expression in mutant model), foundational characterization","pmids":["8175705"],"is_preprint":false},{"year":1995,"finding":"Human β2-chimaerin is a 468-amino acid GTPase-activating protein for p21Rac, localized to chromosome 7p15.3, expressed at high levels in brain and pancreas, and down-regulated in high-grade glioblastoma compared to normal brain and low-grade astrocytoma.","method":"RT-PCR, FISH chromosomal mapping, RNase protection assay, expression profiling in human tissues and tumors","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods establishing identity and chromosomal localization; expression/tumor findings are correlative","pmids":["7614486"],"is_preprint":false},{"year":1997,"finding":"β2-chimaerin binds phorbol esters with high affinity (Kd ~1.9 nM) via its C1 domain in a phosphatidylserine-dependent manner, and translocates from cytosolic to particulate fractions upon phorbol ester treatment in COS-7 cells, establishing it as a novel non-PKC phorbol ester receptor.","method":"Baculovirus expression in Sf9 cells, [3H]phorbol 12,13-dibutyrate binding assay (Scatchard analysis), subcellular fractionation after phorbol ester treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro binding assay with quantitative Kd, replicated with cellular translocation assay","pmids":["9334226"],"is_preprint":false},{"year":1999,"finding":"β2-chimaerin is a high-affinity diacylglycerol (DAG) receptor via its C1 domain; conformationally constrained DAG lactone analogs bind with >100-fold higher affinity than 1-oleoyl-2-acetylglycerol. DAG binding induces translocation to the perinuclear region, and mutation of the conserved Cys-246 in the C1 domain abolishes both binding and translocation.","method":"Binding assays with DAG lactone analogs, GFP-fusion protein imaging (live cell microscopy), site-directed mutagenesis of C1 domain Cys-246, subcellular fractionation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding assay combined with mutagenesis and live-cell imaging demonstrating functional consequence of C1 domain","pmids":["10518540"],"is_preprint":false},{"year":2001,"finding":"Phorbol ester-induced translocation of β2-chimaerin from cytosol to the Golgi apparatus is entirely dependent on the C1 domain (shown by deletional analysis and mutagenesis). Phorbol esters also promote association of β2-chimaerin with Rac in cells, and chimaerin isoforms (α1, β1, β2) share this C1-dependent translocation mechanism.","method":"Subcellular fractionation, fluorescence co-staining with Golgi marker BODIPY-TR-ceramide, deletional analysis, site-directed mutagenesis, co-immunoprecipitation with Rac","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (fractionation, imaging, Co-IP, mutagenesis) with strong mechanistic detail","pmids":["11278894"],"is_preprint":false},{"year":2001,"finding":"β2-chimaerin associates with Tmp21-I (p23), a Golgi-localized anchoring protein, through its C1 domain in a PKC-independent manner. Phorbol esters promote both β2-chimaerin translocation to the perinuclear region and its interaction with Tmp21-I, identifying Tmp21-I as a positional anchor for β2-chimaerin at the Golgi.","method":"Yeast two-hybrid screen to identify interacting proteins, co-immunoprecipitation, deletional analysis of C1 domain requirement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP and Y2H with deletional analysis, single lab study","pmids":["11689559"],"is_preprint":false},{"year":2003,"finding":"β2-chimaerin has Rac-GAP activity specifically for Rac1 (not Cdc42 or RhoA); acidic phospholipids markedly enhance its catalytic activity in vitro. β2-chimaerin reduces cellular Rac-GTP levels and impairs EGF-induced GTP loading onto Rac in COS-1 cells. Deletional and mutagenesis analysis demonstrated that the GAP domain is essential for Rac inactivation. Phorbol ester (PMA) has a dual effect: it increases Rac-GTP levels via PKC, but under PKC inhibition, PMA potentiates β2-chimaerin's Rac-inactivating effect. β2-chimaerin co-localizes and co-immunoprecipitates with active Rac at the plasma membrane.","method":"In vitro GAP activity assay with acidic phospholipids, Rac-GTP pulldown (PAK-PBD) in COS-1 cells, deletional analysis and mutagenesis, co-immunoprecipitation, fluorescence co-localization","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic assay combined with cellular Rac-GTP measurements, mutagenesis, and Co-IP across multiple orthogonal approaches","pmids":["12877655"],"is_preprint":false},{"year":2004,"finding":"Crystal structure of β2-chimaerin at 3.2 Å resolution revealed its inactive conformation: the N-terminus protrudes into the active site of the RacGAP domain, sterically blocking Rac binding. The diacylglycerol/phospholipid binding site on the C1 domain is buried by contacts with the N-terminus, SH2 domain, RacGAP domain, and SH2-C1 linker. Phospholipid binding to the C1 domain triggers cooperative dissociation of these autoinhibitory interactions, allowing the N-terminus to move out of the active site and activate the enzyme — defining the structural mechanism of lipid-dependent allosteric activation.","method":"X-ray crystallography at 3.2 Å resolution of the full-length β2-chimaerin protein","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mechanistic interpretation of autoinhibition and allosteric activation; published in Cell with high citation count","pmids":["15507211"],"is_preprint":false},{"year":2005,"finding":"β2-chimerin inhibits breast cancer cell proliferation and induces G1 cell cycle arrest via its Rac-GAP domain. Adenoviral expression of β2-chimerin in MCF-7 cells reduced Rac-GTP levels, decreased cyclin D1 expression, and caused retinoblastoma protein dephosphorylation. Cells stably expressing constitutively active Rac (V12Rac1), but not RhoA (V14RhoA), were resistant to β2-chimerin-induced cell cycle arrest, establishing Rac as the specific effector.","method":"Adenoviral gene delivery, Rac-GTP pulldown assay, flow cytometry (cell cycle analysis), immunoblotting for cyclin D1 and Rb phosphorylation, stable expression of dominant-active Rac1/RhoA mutants (epistasis)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with active Rac mutant, multiple cellular readouts, and loss-of-function mutagenesis of GAP domain","pmids":["15863513"],"is_preprint":false},{"year":2006,"finding":"β2-chimerin's Rac-GAP activity suppresses heregulin β1 (HRG)-induced ERK activation, mitogenicity, and migration in breast cancer cells. HRG activates Rac through ErbB3/ErbB2 and via transactivation of EGFR (not ErbB4), in a PI3K-dependent, Src-independent manner, and Rac is a critical mediator of this mitogenic signaling; expression of β2-chimerin (inactivating Rac) blocks these responses.","method":"Rac-GTP pulldown assay, ErbB receptor-specific inhibitors and RNAi knockdown, β2-chimerin overexpression, ERK activity assay, cell proliferation and migration assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (RNAi, pharmacological inhibition, overexpression) with defined pathway epistasis","pmids":["16428439"],"is_preprint":false},{"year":2009,"finding":"CHN2 (encoding β2-chimerin) is expressed in insulin-sensitive tissues including adipose tissue, and heterozygous disruption of CHN2 by chromosomal translocation t(7;19)(p15.2;p13.2) results in decreased CHN2 gene expression in patient-derived adipose tissue. Combined haploinsufficiency of CHN2 and INSR causes insulin resistance and intrauterine growth deficiency, implicating CHN2 as a component of proximal insulin signaling in vivo.","method":"FISH breakpoint mapping, gene sequencing, expression studies in patient-derived adipose tissue (gene expression assay), clinical phenotyping of translocation carriers","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 — natural human experiment (chromosomal translocation) with tissue expression validation; mechanistic role in insulin signaling inferred from in vivo data in patient tissue","pmids":["19720790"],"is_preprint":false},{"year":2020,"finding":"In a systems-level family-wide characterization of RhoGAPs, β2-chimaerin (CHN2) was shown to be widely autoinhibited, to form complexes with other Rho regulators for joint network coordination, and to provide positional information for RAC1 signaling. RhoGAPs (including β2-chimaerin) are more promiscuous than RhoGEFs in substrate specificity, serving to confine Rac activity gradients. Integrin adhesions were shown to spatially segregate GEFs and GAPs to shape RAC1 activity zones.","method":"Family-wide substrate specificity assays, interactome mapping (affinity-purification MS), subcellular localization profiling, RAC1 activity biosensors in cells with mechanical stimulation","journal":"Nature cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — large-scale systems study with multiple orthogonal methods; CHN2-specific findings embedded in broader RhoGAP family analysis","pmids":["32203420"],"is_preprint":false}],"current_model":"CHN2 encodes β2-chimaerin, a Rac-specific GTPase-activating protein (RacGAP) that is allosterically autoinhibited in its resting state (N-terminus occludes the RacGAP active site) and activated upon diacylglycerol/phorbol ester binding to its C1 domain, which triggers cooperative unfolding of autoinhibitory contacts and membrane translocation (to Golgi via Tmp21-I anchoring); active β2-chimaerin inactivates Rac1-GTP to suppress downstream proliferative signaling (cyclin D1/Rb/ERK axis) in breast cancer cells and is implicated as a component of proximal insulin signaling in insulin-sensitive tissues in vivo."},"narrative":{"teleology":[{"year":1994,"claim":"Identification of β2-chimaerin as a novel RacGAP with an SH2 domain resolved the question of what protein product the alternatively spliced CHN2 locus encodes and established its neuronal enrichment.","evidence":"cDNA cloning, immunoblotting, subcellular fractionation, and immunohistochemistry in rat cerebellum","pmids":["8175705"],"confidence":"High","gaps":["Mechanism of SH2 domain function in β2-chimaerin remained undefined","Regulation of GAP activity was unknown","Expression and role outside the nervous system not explored"]},{"year":1997,"claim":"Demonstrating high-affinity phorbol ester binding (Kd ~1.9 nM) via the C1 domain and phorbol-ester-induced translocation established β2-chimaerin as a non-PKC diacylglycerol/phorbol ester receptor, answering how lipid second messengers regulate this RacGAP.","evidence":"Baculovirus-expressed protein, quantitative [³H]PDBu binding with Scatchard analysis, subcellular fractionation in COS-7 cells","pmids":["9334226"],"confidence":"High","gaps":["Structural basis of autoinhibition and lipid-dependent activation unresolved","Identity of membrane compartment targeted upon translocation not yet determined"]},{"year":2001,"claim":"Mapping the translocation target to the Golgi apparatus and identifying Tmp21-I as a C1-domain-dependent anchoring partner resolved where β2-chimaerin acts after lipid activation and how it is positionally retained.","evidence":"BODIPY-TR-ceramide Golgi co-staining, yeast two-hybrid screen, co-immunoprecipitation, deletional and site-directed mutagenesis","pmids":["11278894","11689559"],"confidence":"Medium","gaps":["Tmp21-I interaction shown by Y2H and Co-IP in a single lab; independent validation lacking","Functional consequence of Golgi-localized RacGAP activity not tested"]},{"year":2004,"claim":"The 3.2 Å crystal structure revealed the full allosteric mechanism: the N-terminus physically blocks the GAP active site while the C1 lipid-binding pocket is buried, and DAG/phorbol ester binding cooperatively disrupts these contacts, explaining how lipid signals convert the enzyme from an autoinhibited to an active state.","evidence":"X-ray crystallography of full-length β2-chimaerin at 3.2 Å resolution","pmids":["15507211"],"confidence":"High","gaps":["No structure of the activated, Rac-bound complex available","Role of the SH2 domain in autoinhibition or substrate engagement unclear"]},{"year":2005,"claim":"Functional studies in breast cancer cells demonstrated that β2-chimaerin's RacGAP activity causes G1 arrest by reducing cyclin D1 and Rb phosphorylation, with epistasis showing Rac1 (not RhoA) as the specific downstream target, establishing the biological output of this GAP.","evidence":"Adenoviral expression in MCF-7 cells, Rac-GTP pulldown, flow cytometry, immunoblotting, constitutively active Rac1 rescue","pmids":["15863513"],"confidence":"High","gaps":["Whether endogenous β2-chimaerin loss drives tumor progression not directly tested","Relevance beyond breast cancer cell lines unknown"]},{"year":2006,"claim":"Placing β2-chimaerin downstream of ErbB3/ErbB2–PI3K–Rac signaling and showing it blocks heregulin-induced ERK activation and mitogenicity defined the receptor-to-GAP pathway axis it antagonizes.","evidence":"Rac-GTP pulldown, ErbB receptor inhibitors and RNAi, β2-chimaerin overexpression, ERK activity and proliferation/migration assays in breast cancer cells","pmids":["16428439"],"confidence":"High","gaps":["Direct recruitment mechanism from ErbB receptors to β2-chimaerin not identified","SH2 domain role in receptor-proximal signaling not addressed"]},{"year":2009,"claim":"A natural human chromosomal translocation disrupting one CHN2 allele, combined with INSR haploinsufficiency, produced insulin resistance and growth deficiency, providing the first in vivo evidence that β2-chimaerin participates in insulin signaling.","evidence":"FISH breakpoint mapping, gene expression in patient-derived adipose tissue, clinical phenotyping of translocation carriers","pmids":["19720790"],"confidence":"Medium","gaps":["CHN2 haploinsufficiency effect confounded by concurrent INSR haploinsufficiency; isolated CHN2 role not separable","Molecular mechanism linking Rac-GAP activity to insulin signal transduction not defined"]},{"year":2020,"claim":"Systems-level characterization confirmed β2-chimaerin's widespread autoinhibition and revealed that RhoGAPs including CHN2 are more promiscuous than GEFs and shape Rac1 activity gradients by spatial segregation at integrin adhesions, contextualizing CHN2 within the broader Rho signaling network.","evidence":"Family-wide substrate specificity assays, AP-MS interactomics, subcellular localization profiling, RAC1 biosensors with mechanical stimulation","pmids":["32203420"],"confidence":"Medium","gaps":["CHN2-specific interactors and substrates not individually resolved in this family-wide study","Extent of promiscuity of β2-chimaerin toward GTPases other than Rac1 not quantitatively defined"]},{"year":null,"claim":"Major open questions remain: the SH2 domain's specific binding partners and contribution to signaling or autoinhibition are undefined, no activated/Rac-bound structure exists, and the physiological role of β2-chimaerin in insulin signaling independent of INSR requires validation in animal models.","evidence":"","pmids":[],"confidence":"High","gaps":["SH2 domain function uncharacterized despite being a distinguishing feature of β2-chimaerin","No structure of Rac1-bound activated complex","In vivo role in insulin signaling confounded by co-disruption of INSR"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,6,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[6,8,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,8,9,11]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,3,7]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,6]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,8,9,10,11]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[8]}],"complexes":[],"partners":["RAC1","TMED10","ERBB2","ERBB3"],"other_free_text":[]},"mechanistic_narrative":"CHN2 encodes β2-chimaerin, a Rac1-specific GTPase-activating protein (RacGAP) that converts Rac1-GTP to its inactive GDP-bound state, thereby attenuating Rac-dependent proliferative, migratory, and mitogenic signaling cascades [PMID:12877655, PMID:15863513]. In its resting state, the protein is autoinhibited: crystallography revealed that the N-terminus occludes the RacGAP catalytic site while the C1 domain lipid-binding pocket is buried by intramolecular contacts, and diacylglycerol or phorbol ester binding to the C1 domain triggers cooperative unfolding of these autoinhibitory interactions, membrane translocation to the Golgi (via the anchor protein Tmp21-I), and enzymatic activation [PMID:15507211, PMID:9334226, PMID:11689559]. Active β2-chimaerin suppresses Rac1-GTP levels downstream of ErbB receptors, reducing cyclin D1 expression, Rb phosphorylation, and ERK activation to enforce G1 cell cycle arrest in breast cancer cells [PMID:15863513, PMID:16428439]. Heterozygous disruption of CHN2 by chromosomal translocation, combined with INSR haploinsufficiency, causes insulin resistance and intrauterine growth deficiency, implicating β2-chimaerin in proximal insulin signaling in vivo [PMID:19720790]."},"prefetch_data":{"uniprot":{"accession":"P52757","full_name":"Beta-chimaerin","aliases":["Beta-chimerin","Rho GTPase-activating protein 3"],"length_aa":468,"mass_kda":53.9,"function":"GTPase-activating protein for p21-rac. Insufficient expression of beta-2 chimaerin is expected to lead to higher Rac activity and could therefore play a role in the progression from low-grade to high-grade tumors","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P52757/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHN2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CHN2","total_profiled":1310},"omim":[{"mim_id":"618184","title":"NEUROPATHY, CONGENITAL HYPOMYELINATING, 2; CHN2","url":"https://www.omim.org/entry/618184"},{"mim_id":"605253","title":"NEUROPATHY, CONGENITAL HYPOMYELINATING, 1, AUTOSOMAL RECESSIVE; CHN1","url":"https://www.omim.org/entry/605253"},{"mim_id":"602857","title":"CHIMERIN 2; CHN2","url":"https://www.omim.org/entry/602857"},{"mim_id":"159440","title":"MYELIN PROTEIN ZERO; MPZ","url":"https://www.omim.org/entry/159440"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":170.8},{"tissue":"intestine","ntpm":72.2}],"url":"https://www.proteinatlas.org/search/CHN2"},"hgnc":{"alias_symbol":["ARHGAP3","RhoGAP3"],"prev_symbol":[]},"alphafold":{"accession":"P52757","domains":[{"cath_id":"3.30.505.10","chopping":"31-145","consensus_level":"high","plddt":94.8309,"start":31,"end":145},{"cath_id":"3.30.60.20","chopping":"149-159_210-265","consensus_level":"medium","plddt":87.4363,"start":149,"end":265},{"cath_id":"1.10.555.10","chopping":"285-465","consensus_level":"high","plddt":95.1323,"start":285,"end":465}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P52757","model_url":"https://alphafold.ebi.ac.uk/files/AF-P52757-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P52757-F1-predicted_aligned_error_v6.png","plddt_mean":84.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHN2","jax_strain_url":"https://www.jax.org/strain/search?query=CHN2"},"sequence":{"accession":"P52757","fasta_url":"https://rest.uniprot.org/uniprotkb/P52757.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P52757/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P52757"}},"corpus_meta":[{"pmid":"10092476","id":"PMC_10092476","title":"Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2.","date":"1999","source":"Experimental parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/10092476","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17020538","id":"PMC_17020538","title":"The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17020538","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7871486","id":"PMC_7871486","title":"In vitro embryotoxicity of the cysteine proteinase inhibitors benzyloxycarbonyl-phenylalanine-alanine-diazomethane (Z-Phe-Ala-CHN2) and benzyloxycarbonyl-phenylalanine-phenylalanine-diazomethane (Z-Phe-Phe-CHN2).","date":"1994","source":"Teratology","url":"https://pubmed.ncbi.nlm.nih.gov/7871486","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19720790","id":"PMC_19720790","title":"Severe insulin resistance and intrauterine growth deficiency associated with haploinsufficiency for INSR and CHN2: new insights into synergistic pathways involved in growth and metabolism.","date":"2009","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/19720790","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17328798","id":"PMC_17328798","title":"The cysteine proteinase inhibitor Z-Phe-Ala-CHN2 alters cell morphology and cell division activity of Trypanosoma brucei bloodstream forms in vivo.","date":"2007","source":"Kinetoplastid biology and disease","url":"https://pubmed.ncbi.nlm.nih.gov/17328798","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31228090","id":"PMC_31228090","title":"Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).","date":"2019","source":"Diabetes therapy : research, treatment and education of diabetes and related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31228090","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29719347","id":"PMC_29719347","title":"CHN2 Promoter Methylation Change May Be Associated With Methamphetamine Dependence.","date":"2017","source":"Shanghai archives of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29719347","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23941981","id":"PMC_23941981","title":"Association of a novel polymorphism of the β2-chimaerin gene (CHN2) with smoking.","date":"2013","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/23941981","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37507904","id":"PMC_37507904","title":"Neuroprotective and Antioxidant Properties of CholesteroNitrone ChN2 and QuinolylNitrone QN23 in an Experimental Model of Cerebral Ischemia: Involvement of Necrotic and Apoptotic Cell Death.","date":"2023","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37507904","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34870792","id":"PMC_34870792","title":"Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.","date":"2021","source":"Diabetes therapy : research, treatment and education of diabetes and related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/34870792","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16273093","id":"PMC_16273093","title":"A quantitative protein interaction network for the ErbB receptors using protein microarrays.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16273093","citation_count":568,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15761153","id":"PMC_15761153","title":"High-throughput mapping of a dynamic signaling network in mammalian cells.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15761153","citation_count":553,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23251661","id":"PMC_23251661","title":"Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23251661","citation_count":312,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18519826","id":"PMC_18519826","title":"Molecular genetics of successful smoking cessation: convergent genome-wide association study results.","date":"2008","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18519826","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32203420","id":"PMC_32203420","title":"Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32203420","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12853948","id":"PMC_12853948","title":"The DNA sequence of human chromosome 7.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12853948","citation_count":188,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12690205","id":"PMC_12690205","title":"Human chromosome 7: DNA sequence and biology.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12690205","citation_count":154,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20379614","id":"PMC_20379614","title":"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.","date":"2010","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/20379614","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15507211","id":"PMC_15507211","title":"Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15507211","citation_count":105,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10518540","id":"PMC_10518540","title":"beta2-chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10518540","citation_count":90,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9334226","id":"PMC_9334226","title":"Beta2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9334226","citation_count":90,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12877655","id":"PMC_12877655","title":"Characterization of the Rac-GAP (Rac-GTPase-activating protein) activity of beta2-chimaerin, a 'non-protein kinase C' phorbol ester receptor.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12877655","citation_count":82,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15863513","id":"PMC_15863513","title":"Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15863513","citation_count":69,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16428439","id":"PMC_16428439","title":"Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16428439","citation_count":68,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11278894","id":"PMC_11278894","title":"Phorbol esters and related analogs regulate the subcellular localization of beta 2-chimaerin, a non-protein kinase C phorbol ester receptor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278894","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25814554","id":"PMC_25814554","title":"Phospho-tyrosine dependent protein-protein interaction network.","date":"2015","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/25814554","citation_count":61,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"37071682","id":"PMC_37071682","title":"Cross-linking mass spectrometry discovers, evaluates, and corroborates structures and protein-protein interactions in the human cell.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37071682","citation_count":60,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8175705","id":"PMC_8175705","title":"Cerebellar beta 2-chimaerin, a GTPase-activating protein for p21 ras-related rac is specifically expressed in granule cells and has a unique N-terminal SH2 domain.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8175705","citation_count":59,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7614486","id":"PMC_7614486","title":"Identification and characterization of human beta 2-chimaerin: association with malignant transformation in astrocytoma.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7614486","citation_count":54,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11689559","id":"PMC_11689559","title":"Chimaerins, novel non-protein kinase C phorbol ester receptors, associate with Tmp21-I (p23): evidence for a novel anchoring mechanism involving the chimaerin C1 domain.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11689559","citation_count":53,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6994,"output_tokens":344,"usd":0.013071},"stage2":{"model":"claude-opus-4-6","input_tokens":3488,"output_tokens":642,"usd":0.050235},"total_usd":0.27729,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":20551,"output_tokens":4374,"usd":0.063631},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7157,"output_tokens":2578,"usd":0.150353}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"CHN2 (encoding beta-2 chimerin, a Rac-specific GTPase-activating protein) is expressed in insulin-sensitive tissues, and its haploinsufficiency due to chromosomal translocation results in decreased CHN2 gene expression in patient-derived adipose tissue, implicating CHN2 as a component of proximal insulin signaling in vivo.\",\n      \"method\": \"FISH breakpoint mapping, sequencing, and gene expression studies in patient-derived adipose tissue from individuals carrying a t(7;19)(p15.2;p13.2) translocation disrupting CHN2\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct patient-derived tissue expression data with chromosomal disruption establishing pathway placement, but single study, no in vitro reconstitution\",\n      \"pmids\": [\"19720790\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHN2 encodes beta-2 chimerin, a Rac-specific GTPase-activating protein expressed in insulin-sensitive tissues that participates in proximal insulin signaling, as demonstrated by haploinsufficiency causing reduced expression in adipose tissue and contributing to insulin resistance and growth deficiency in a digenic human disease context.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries from KEEP papers only.\n\n**Classification:**\n\nRetrieved papers:\n1. Z-Phe-Ala-CHN2 = chemical inhibitor name, not CHN2 gene → EXCLUDE (alias collision)\n2. Gly-Phe-CHN2 = chemical inhibitor name → EXCLUDE (alias collision)\n3. Z-Phe-Ala-CHN2 / Z-Phe-Phe-CHN2 = chemical inhibitors → EXCLUDE (alias collision)\n4. CHN2 gene (β2-chimerin), insulin resistance/growth — KEEP\n5. Z-Phe-Ala-CHN2 = chemical inhibitor → EXCLUDE (alias collision)\n6. AWARD-CHN2 = clinical trial name, not CHN2 gene → EXCLUDE (alias collision)\n7. CHN2 promoter methylation and MA dependence — KEEP (but no mechanistic findings, only association)\n8. CHN2 polymorphism and smoking — KEEP (but no mechanistic findings, only association)\n9. ChN2 = cholesteronitrone 2, a chemical compound → EXCLUDE (alias collision)\n10. AWARD-CHN2 = clinical trial name → EXCLUDE (alias collision)\n\nGene2pubmed curated papers:\n1. General human interactome (CHN2 may appear) — KEEP if mechanistic CHN2 data present; large-scale screen, no CHN2-specific mechanism → EXCLUDE\n2. MGC cDNA sequences — no mechanistic data → EXCLUDE\n3. BioPlex 2.0 — large-scale interactome, no CHN2-specific mechanism → EXCLUDE\n4. HuRI — large-scale interactome → EXCLUDE\n5. FLJ cDNA collection → EXCLUDE\n6. BioPlex 3.0 → EXCLUDE\n7. GO phylogenetic propagation → EXCLUDE\n8. ErbB receptor protein microarrays — no CHN2-specific mechanism → EXCLUDE\n9. LUMIER TGFβ pathway — no CHN2-specific mechanism → EXCLUDE\n10. MGC status paper → EXCLUDE\n11. Alternative promoters — no CHN2-specific mechanism → EXCLUDE\n12. Normalization/subtraction cDNA → EXCLUDE\n13. GWAS childhood obesity → EXCLUDE\n14. GWAS smoking cessation → EXCLUDE\n15. RhoGEF/RhoGAP systems analysis — CHN2/β2-chimaerin characterized as RhoGAP → KEEP\n16. Chromosome 7 DNA sequence → EXCLUDE\n17. Human chromosome 7 biology → EXCLUDE\n18. Personalized smoking cessation GWAS → EXCLUDE\n19. Crystal structure of β2-chimaerin — KEEP\n20. β2-chimaerin DAG binding and subcellular localization — KEEP\n21. β2-chimaerin phorbol ester receptor — KEEP\n22. Rac-GAP activity of β2-chimaerin — KEEP\n23. β2-chimerin inhibits breast cancer proliferation — KEEP\n24. β2-chimerin in HRG signaling — KEEP\n25. Phorbol ester regulation of β2-chimaerin localization — KEEP\n26. Phospho-tyrosine PPI network — large-scale screen, no CHN2-specific mechanism → EXCLUDE\n27. XL-MS structural proteome — large-scale, no CHN2-specific mechanism → EXCLUDE\n28. Cerebellar β2-chimaerin identification — KEEP\n29. Human β2-chimaerin identification, astrocytoma — KEEP\n30. Chimaerins associate with Tmp21-I — KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"β2-chimaerin (CHN2) was identified as a 46-kDa RacGAP protein specifically expressed in cerebellar granule cells, possessing an N-terminal SH2 domain generated by alternative splicing of the beta-chimaerin gene. It is enriched in particulate/synaptosomal fractions and its expression increases postnatally.\",\n      \"method\": \"cDNA cloning, PCR, immunoblotting, subcellular fractionation, immunohistochemistry in rat cerebellum and mouse weaver mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (cloning, fractionation, expression in mutant model), foundational characterization\",\n      \"pmids\": [\"8175705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Human β2-chimaerin is a 468-amino acid GTPase-activating protein for p21Rac, localized to chromosome 7p15.3, expressed at high levels in brain and pancreas, and down-regulated in high-grade glioblastoma compared to normal brain and low-grade astrocytoma.\",\n      \"method\": \"RT-PCR, FISH chromosomal mapping, RNase protection assay, expression profiling in human tissues and tumors\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods establishing identity and chromosomal localization; expression/tumor findings are correlative\",\n      \"pmids\": [\"7614486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"β2-chimaerin binds phorbol esters with high affinity (Kd ~1.9 nM) via its C1 domain in a phosphatidylserine-dependent manner, and translocates from cytosolic to particulate fractions upon phorbol ester treatment in COS-7 cells, establishing it as a novel non-PKC phorbol ester receptor.\",\n      \"method\": \"Baculovirus expression in Sf9 cells, [3H]phorbol 12,13-dibutyrate binding assay (Scatchard analysis), subcellular fractionation after phorbol ester treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro binding assay with quantitative Kd, replicated with cellular translocation assay\",\n      \"pmids\": [\"9334226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"β2-chimaerin is a high-affinity diacylglycerol (DAG) receptor via its C1 domain; conformationally constrained DAG lactone analogs bind with >100-fold higher affinity than 1-oleoyl-2-acetylglycerol. DAG binding induces translocation to the perinuclear region, and mutation of the conserved Cys-246 in the C1 domain abolishes both binding and translocation.\",\n      \"method\": \"Binding assays with DAG lactone analogs, GFP-fusion protein imaging (live cell microscopy), site-directed mutagenesis of C1 domain Cys-246, subcellular fractionation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding assay combined with mutagenesis and live-cell imaging demonstrating functional consequence of C1 domain\",\n      \"pmids\": [\"10518540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Phorbol ester-induced translocation of β2-chimaerin from cytosol to the Golgi apparatus is entirely dependent on the C1 domain (shown by deletional analysis and mutagenesis). Phorbol esters also promote association of β2-chimaerin with Rac in cells, and chimaerin isoforms (α1, β1, β2) share this C1-dependent translocation mechanism.\",\n      \"method\": \"Subcellular fractionation, fluorescence co-staining with Golgi marker BODIPY-TR-ceramide, deletional analysis, site-directed mutagenesis, co-immunoprecipitation with Rac\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (fractionation, imaging, Co-IP, mutagenesis) with strong mechanistic detail\",\n      \"pmids\": [\"11278894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"β2-chimaerin associates with Tmp21-I (p23), a Golgi-localized anchoring protein, through its C1 domain in a PKC-independent manner. Phorbol esters promote both β2-chimaerin translocation to the perinuclear region and its interaction with Tmp21-I, identifying Tmp21-I as a positional anchor for β2-chimaerin at the Golgi.\",\n      \"method\": \"Yeast two-hybrid screen to identify interacting proteins, co-immunoprecipitation, deletional analysis of C1 domain requirement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and Y2H with deletional analysis, single lab study\",\n      \"pmids\": [\"11689559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"β2-chimaerin has Rac-GAP activity specifically for Rac1 (not Cdc42 or RhoA); acidic phospholipids markedly enhance its catalytic activity in vitro. β2-chimaerin reduces cellular Rac-GTP levels and impairs EGF-induced GTP loading onto Rac in COS-1 cells. Deletional and mutagenesis analysis demonstrated that the GAP domain is essential for Rac inactivation. Phorbol ester (PMA) has a dual effect: it increases Rac-GTP levels via PKC, but under PKC inhibition, PMA potentiates β2-chimaerin's Rac-inactivating effect. β2-chimaerin co-localizes and co-immunoprecipitates with active Rac at the plasma membrane.\",\n      \"method\": \"In vitro GAP activity assay with acidic phospholipids, Rac-GTP pulldown (PAK-PBD) in COS-1 cells, deletional analysis and mutagenesis, co-immunoprecipitation, fluorescence co-localization\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay combined with cellular Rac-GTP measurements, mutagenesis, and Co-IP across multiple orthogonal approaches\",\n      \"pmids\": [\"12877655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structure of β2-chimaerin at 3.2 Å resolution revealed its inactive conformation: the N-terminus protrudes into the active site of the RacGAP domain, sterically blocking Rac binding. The diacylglycerol/phospholipid binding site on the C1 domain is buried by contacts with the N-terminus, SH2 domain, RacGAP domain, and SH2-C1 linker. Phospholipid binding to the C1 domain triggers cooperative dissociation of these autoinhibitory interactions, allowing the N-terminus to move out of the active site and activate the enzyme — defining the structural mechanism of lipid-dependent allosteric activation.\",\n      \"method\": \"X-ray crystallography at 3.2 Å resolution of the full-length β2-chimaerin protein\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mechanistic interpretation of autoinhibition and allosteric activation; published in Cell with high citation count\",\n      \"pmids\": [\"15507211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"β2-chimerin inhibits breast cancer cell proliferation and induces G1 cell cycle arrest via its Rac-GAP domain. Adenoviral expression of β2-chimerin in MCF-7 cells reduced Rac-GTP levels, decreased cyclin D1 expression, and caused retinoblastoma protein dephosphorylation. Cells stably expressing constitutively active Rac (V12Rac1), but not RhoA (V14RhoA), were resistant to β2-chimerin-induced cell cycle arrest, establishing Rac as the specific effector.\",\n      \"method\": \"Adenoviral gene delivery, Rac-GTP pulldown assay, flow cytometry (cell cycle analysis), immunoblotting for cyclin D1 and Rb phosphorylation, stable expression of dominant-active Rac1/RhoA mutants (epistasis)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with active Rac mutant, multiple cellular readouts, and loss-of-function mutagenesis of GAP domain\",\n      \"pmids\": [\"15863513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"β2-chimerin's Rac-GAP activity suppresses heregulin β1 (HRG)-induced ERK activation, mitogenicity, and migration in breast cancer cells. HRG activates Rac through ErbB3/ErbB2 and via transactivation of EGFR (not ErbB4), in a PI3K-dependent, Src-independent manner, and Rac is a critical mediator of this mitogenic signaling; expression of β2-chimerin (inactivating Rac) blocks these responses.\",\n      \"method\": \"Rac-GTP pulldown assay, ErbB receptor-specific inhibitors and RNAi knockdown, β2-chimerin overexpression, ERK activity assay, cell proliferation and migration assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (RNAi, pharmacological inhibition, overexpression) with defined pathway epistasis\",\n      \"pmids\": [\"16428439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CHN2 (encoding β2-chimerin) is expressed in insulin-sensitive tissues including adipose tissue, and heterozygous disruption of CHN2 by chromosomal translocation t(7;19)(p15.2;p13.2) results in decreased CHN2 gene expression in patient-derived adipose tissue. Combined haploinsufficiency of CHN2 and INSR causes insulin resistance and intrauterine growth deficiency, implicating CHN2 as a component of proximal insulin signaling in vivo.\",\n      \"method\": \"FISH breakpoint mapping, gene sequencing, expression studies in patient-derived adipose tissue (gene expression assay), clinical phenotyping of translocation carriers\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — natural human experiment (chromosomal translocation) with tissue expression validation; mechanistic role in insulin signaling inferred from in vivo data in patient tissue\",\n      \"pmids\": [\"19720790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In a systems-level family-wide characterization of RhoGAPs, β2-chimaerin (CHN2) was shown to be widely autoinhibited, to form complexes with other Rho regulators for joint network coordination, and to provide positional information for RAC1 signaling. RhoGAPs (including β2-chimaerin) are more promiscuous than RhoGEFs in substrate specificity, serving to confine Rac activity gradients. Integrin adhesions were shown to spatially segregate GEFs and GAPs to shape RAC1 activity zones.\",\n      \"method\": \"Family-wide substrate specificity assays, interactome mapping (affinity-purification MS), subcellular localization profiling, RAC1 activity biosensors in cells with mechanical stimulation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — large-scale systems study with multiple orthogonal methods; CHN2-specific findings embedded in broader RhoGAP family analysis\",\n      \"pmids\": [\"32203420\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHN2 encodes β2-chimaerin, a Rac-specific GTPase-activating protein (RacGAP) that is allosterically autoinhibited in its resting state (N-terminus occludes the RacGAP active site) and activated upon diacylglycerol/phorbol ester binding to its C1 domain, which triggers cooperative unfolding of autoinhibitory contacts and membrane translocation (to Golgi via Tmp21-I anchoring); active β2-chimaerin inactivates Rac1-GTP to suppress downstream proliferative signaling (cyclin D1/Rb/ERK axis) in breast cancer cells and is implicated as a component of proximal insulin signaling in insulin-sensitive tissues in vivo.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CHN2 encodes beta-2 chimerin, a Rac-specific GTPase-activating protein expressed in insulin-sensitive tissues that functions in proximal insulin signaling [PMID:19720790]. Haploinsufficiency of CHN2 due to chromosomal translocation results in decreased expression in adipose tissue and is associated with insulin resistance and growth deficiency [PMID:19720790].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying CHN2 as a participant in insulin signaling resolved how Rac-GAP activity connects to metabolic regulation in vivo, establishing that reduced CHN2 expression in adipose tissue accompanies insulin resistance.\",\n      \"evidence\": \"FISH breakpoint mapping, sequencing, and gene expression analysis in patient-derived adipose tissue from individuals carrying a t(7;19)(p15.2;p13.2) translocation disrupting CHN2\",\n      \"pmids\": [\"19720790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single study without independent replication or in vitro reconstitution of the insulin-signaling mechanism\",\n        \"Specific Rac-dependent downstream effectors mediating the metabolic phenotype are not defined\",\n        \"Whether the phenotype is monogenic (CHN2 alone) or requires digenic contribution from the second disrupted locus is not resolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The precise molecular mechanism by which beta-2 chimerin's Rac-GAP activity modulates insulin signaling, including substrate specificity among Rac isoforms and the relevant downstream effectors in adipose tissue, remains uncharacterized.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No biochemical reconstitution of CHN2 in insulin signaling pathway\",\n        \"No animal knockout model characterizing metabolic phenotype\",\n        \"Structural basis for CHN2 regulation and activation in insulin-responsive cells is unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0098772\",\n        \"supporting_discovery_ids\": [0]\n      }\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\n        \"term_id\": \"R-HSA-162582\",\n        \"supporting_discovery_ids\": [0]\n      }\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CHN2 encodes β2-chimaerin, a Rac1-specific GTPase-activating protein (RacGAP) that converts Rac1-GTP to its inactive GDP-bound state, thereby attenuating Rac-dependent proliferative, migratory, and mitogenic signaling cascades [PMID:12877655, PMID:15863513]. In its resting state, the protein is autoinhibited: crystallography revealed that the N-terminus occludes the RacGAP catalytic site while the C1 domain lipid-binding pocket is buried by intramolecular contacts, and diacylglycerol or phorbol ester binding to the C1 domain triggers cooperative unfolding of these autoinhibitory interactions, membrane translocation to the Golgi (via the anchor protein Tmp21-I), and enzymatic activation [PMID:15507211, PMID:9334226, PMID:11689559]. Active β2-chimaerin suppresses Rac1-GTP levels downstream of ErbB receptors, reducing cyclin D1 expression, Rb phosphorylation, and ERK activation to enforce G1 cell cycle arrest in breast cancer cells [PMID:15863513, PMID:16428439]. Heterozygous disruption of CHN2 by chromosomal translocation, combined with INSR haploinsufficiency, causes insulin resistance and intrauterine growth deficiency, implicating β2-chimaerin in proximal insulin signaling in vivo [PMID:19720790].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of β2-chimaerin as a novel RacGAP with an SH2 domain resolved the question of what protein product the alternatively spliced CHN2 locus encodes and established its neuronal enrichment.\",\n      \"evidence\": \"cDNA cloning, immunoblotting, subcellular fractionation, and immunohistochemistry in rat cerebellum\",\n      \"pmids\": [\"8175705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism of SH2 domain function in β2-chimaerin remained undefined\",\n        \"Regulation of GAP activity was unknown\",\n        \"Expression and role outside the nervous system not explored\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating high-affinity phorbol ester binding (Kd ~1.9 nM) via the C1 domain and phorbol-ester-induced translocation established β2-chimaerin as a non-PKC diacylglycerol/phorbol ester receptor, answering how lipid second messengers regulate this RacGAP.\",\n      \"evidence\": \"Baculovirus-expressed protein, quantitative [³H]PDBu binding with Scatchard analysis, subcellular fractionation in COS-7 cells\",\n      \"pmids\": [\"9334226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of autoinhibition and lipid-dependent activation unresolved\",\n        \"Identity of membrane compartment targeted upon translocation not yet determined\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapping the translocation target to the Golgi apparatus and identifying Tmp21-I as a C1-domain-dependent anchoring partner resolved where β2-chimaerin acts after lipid activation and how it is positionally retained.\",\n      \"evidence\": \"BODIPY-TR-ceramide Golgi co-staining, yeast two-hybrid screen, co-immunoprecipitation, deletional and site-directed mutagenesis\",\n      \"pmids\": [\"11278894\", \"11689559\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Tmp21-I interaction shown by Y2H and Co-IP in a single lab; independent validation lacking\",\n        \"Functional consequence of Golgi-localized RacGAP activity not tested\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The 3.2 Å crystal structure revealed the full allosteric mechanism: the N-terminus physically blocks the GAP active site while the C1 lipid-binding pocket is buried, and DAG/phorbol ester binding cooperatively disrupts these contacts, explaining how lipid signals convert the enzyme from an autoinhibited to an active state.\",\n      \"evidence\": \"X-ray crystallography of full-length β2-chimaerin at 3.2 Å resolution\",\n      \"pmids\": [\"15507211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structure of the activated, Rac-bound complex available\",\n        \"Role of the SH2 domain in autoinhibition or substrate engagement unclear\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Functional studies in breast cancer cells demonstrated that β2-chimaerin's RacGAP activity causes G1 arrest by reducing cyclin D1 and Rb phosphorylation, with epistasis showing Rac1 (not RhoA) as the specific downstream target, establishing the biological output of this GAP.\",\n      \"evidence\": \"Adenoviral expression in MCF-7 cells, Rac-GTP pulldown, flow cytometry, immunoblotting, constitutively active Rac1 rescue\",\n      \"pmids\": [\"15863513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether endogenous β2-chimaerin loss drives tumor progression not directly tested\",\n        \"Relevance beyond breast cancer cell lines unknown\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placing β2-chimaerin downstream of ErbB3/ErbB2–PI3K–Rac signaling and showing it blocks heregulin-induced ERK activation and mitogenicity defined the receptor-to-GAP pathway axis it antagonizes.\",\n      \"evidence\": \"Rac-GTP pulldown, ErbB receptor inhibitors and RNAi, β2-chimaerin overexpression, ERK activity and proliferation/migration assays in breast cancer cells\",\n      \"pmids\": [\"16428439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct recruitment mechanism from ErbB receptors to β2-chimaerin not identified\",\n        \"SH2 domain role in receptor-proximal signaling not addressed\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A natural human chromosomal translocation disrupting one CHN2 allele, combined with INSR haploinsufficiency, produced insulin resistance and growth deficiency, providing the first in vivo evidence that β2-chimaerin participates in insulin signaling.\",\n      \"evidence\": \"FISH breakpoint mapping, gene expression in patient-derived adipose tissue, clinical phenotyping of translocation carriers\",\n      \"pmids\": [\"19720790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"CHN2 haploinsufficiency effect confounded by concurrent INSR haploinsufficiency; isolated CHN2 role not separable\",\n        \"Molecular mechanism linking Rac-GAP activity to insulin signal transduction not defined\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Systems-level characterization confirmed β2-chimaerin's widespread autoinhibition and revealed that RhoGAPs including CHN2 are more promiscuous than GEFs and shape Rac1 activity gradients by spatial segregation at integrin adhesions, contextualizing CHN2 within the broader Rho signaling network.\",\n      \"evidence\": \"Family-wide substrate specificity assays, AP-MS interactomics, subcellular localization profiling, RAC1 biosensors with mechanical stimulation\",\n      \"pmids\": [\"32203420\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"CHN2-specific interactors and substrates not individually resolved in this family-wide study\",\n        \"Extent of promiscuity of β2-chimaerin toward GTPases other than Rac1 not quantitatively defined\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions remain: the SH2 domain's specific binding partners and contribution to signaling or autoinhibition are undefined, no activated/Rac-bound structure exists, and the physiological role of β2-chimaerin in insulin signaling independent of INSR requires validation in animal models.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"SH2 domain function uncharacterized despite being a distinguishing feature of β2-chimaerin\",\n        \"No structure of Rac1-bound activated complex\",\n        \"In vivo role in insulin signaling confounded by co-disruption of INSR\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 6, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6, 8, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 8, 9, 11]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 3, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 8, 9, 10, 11]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RAC1\",\n      \"TMED10\",\n      \"ERBB2\",\n      \"ERBB3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}